A
Alcista
Alcista · 25%CDNA
$18.57
Precio del escenario
$64.000
-2.566 (-4.01%)Al cierre
Loading chart…
- Máximo
- 68.090
- Apertura
- 66.340
- Precio medio ponderado por volumen
- 64.98
- Volumen
- 1.50M
- Capitalización
- 751.03M
- Mínimo
- 62.850
- Importe
- 97.38M
- EV/EBITDA, TTM
- 148.51
CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Análisis de IA of CareDx, Inc. (CDNA)
ComprarCareDx Inc is a good buy right now due to its strong recent performance and positive financial indicators. The current price is $63.67, with a significant year-to-date change of +232.65%. Additionally, the company reported a gross margin of 73.50% in Q2 2026, reflecting operational efficiency and profitability. The main risk is the forward P/E ratio of 156.25, indicating high expectations that may not be met if growth slows.
Recomendaciones de analistas (3)
-71.88% Potencial de caída
Comprar
3 Comprar
0 Mantener
0 Vender
Actual: 64.00
Mínimo
18.00
Promedio
18.00
Máximo
18.00
BTIG
Comprar
$74
2026-09-24
BTIG
2026-09-24
Precio objetivo
$74
Comprar
Canaccord
Comprar
$65
2026-09-02
Canaccord
2026-09-02
Precio objetivo
$65
Comprar
BTIG
Comprar
$60
2026-08-06
BTIG
2026-08-06
Precio objetivo
$60
Comprar
Craig-Hallum
Comprar
$64
2026-08-03
Craig-Hallum
2026-08-03
Precio objetivo
$64
Comprar
Craig-Hallum
Mantener
$35
2026-07-16
Craig-Hallum
2026-07-16
Precio objetivo
$35
Mantener
Métricas de valoración
El PER previsto actual de CareDx, Inc. (CDNA) es 156.25, frente a su media de 5 años de 3.34.
Escenarios de precio de Alphio AI para CDNA
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con CDNA en cartera
Cronología de eventos
Noticias
8.510-10stocktwitsARK Invest Restructures Tech and Biotech Holdings
7.510-06stocktwitsCathie Wood Reshuffles Biotech Portfolio Amid Market Movements
4.509-24NASDAQ.COMARK Genomic Revolution ETF Outperforms with Notable Gains
6.008-28NASDAQ.COMCareDx Inc Stock Surpasses Analyst Target Price
6.008-03stocktwitsBTIG Raises Snowflake Price Target to $340, Maintains Buy Rating
Preguntas frecuentes sobre CDNA, respondidas por Alphio AI
CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).
CareDx Inc is a good buy right now due to its strong recent performance and positive financial indicators. The current price is $63.67, with a significant year-to-date change of +232.65%. Additionally, the company reported a gross margin of 73.50% in Q2 2026, reflecting operational efficiency and profitability. The main risk is the forward P/E ratio of 156.25, indicating high expectations that may not be met if growth slows.
3 analysts cover CDNA: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 18.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.